George Scangos Named Biogen Idec’s CEO- Not Entirely a Head Scratcher

Jason Chew June 30, 2010- Geoge Scangos from Exelixis was officially named CEO of Biogen, replacing James Mullen who retired June 8 under pressure from the board. He has biologics.

Calistoga Pharmaceuticals and Plexxikon- Two Biotechs to Keep an Eye On

Jason Chew Calistoga and Plexxikon are on the leading edge of two of the hottest targets in drug development today. Both are privately held. Seattle based Calistoga Pharmaceuticals was founded.

Bristol-Myers Squibb- High Dividend, Zero Growth

Jason Chew With a 5% dividend, Bristol-Myers Squibb provides one the highest yields you can find. This makes BMY a very attractive stock for income investors, especially considering today’s near-zero.

Anthera Pharmaceuticals- IPO, What’s Next?

Jason Chew After the 2000 bubble and crash, the biotech IPO has finally begun to crack open a bit. First, Ironwood tested the waters in February with the largest IPO.

Cubist vs. Hatch-Waxman

In 2003, Cubist was granted approval for its novel antibiotic, Cubicin, for complicated skin and skin structure infections by Gram-positive bacteria, including drug-resistant strains. Over the next couple years, the.

Targacept- Ready to Take Off

Jason Chew Targacept is a company focused on CNS diseases and disorders, targeting Neuronal Nicotinic Receptors (NNRs). As a company spun off from R.J Reynolds and still located in Winston-Salem,.

Curis Drug GDC-0449 Fails Colorectal Trial

Jason Chew Curis released results today for its hedghog pathway inhibitor GDC-0449 in a pivotal Phase II colorectal trial run by Roche. The company said its drug failed to extend the.

Ariad is Set For Success

Jason Chew For years, much of Ariad’s value had been tied to its mTOR inhibitor, Ridaforolimus. Ridaforolimus is an orally bio-available analog of Rapamycin- an immunosuppresent discovered decades ago- the.

Genomic Health- Possible Takeover Candidate

Jason Chew Genomic Health is a pure-play oncology in-vitro diagnostics company with approved products and a pipeline to drive future growth. It fits in well with the growing importance of.

Celldex Sets it Straight at ASCO

After Celldex’s flubbed pre-ASCO abstract release led investor to question interim Phase II data for its cancer vaccine CDX-110 (PF-04948568), also with the generic name Rindopepimut, they made sure to.

Vivus Has a Hit in Qnexa

Obesity has a high prevalence in the US and is now frequently cited as being a national health issue. It is on the rise in almost every industrialized and some.

Investment Opportunities in Women’s Health

The next several months will be an exciting time for the women’s health space, with several important events that may represent an opportunity for investors. Most notably, Pfizer (PFE) has.

Alexion Pharmaceuticals- Poster Child for Ultra-orphan Treatments

Alexion got some good news today, receiving earlier than expected approval for its drug, Soliris (eculizumab), for the treatment of PNH in Japan- the world’s second largest pharmaceuticals market. Having.

Roche- Leading the Way in Personalized Medicine

(Featured in TheBigRedBiotechBlog) This Swiss pharma is the third largest pharmaceutical company both by revenue and market cap. It is one of the fastest growing companies in its peer group,.

Next Generation Antibody Technologies- Seattle Genetics Leads the Way

Next Generation Antibody Technologies- Seattle Genetics Leads the Way Monoclonal Antibody Technology has revolutionized medicine. Since 1986, more than 20 Antibody drugs have been approved, with sales of $26 Billion.

Incyte Pharmaceuticals: JAK it Up

Incyte Pharmaceuticals: JAK it Up Incyte Pharmaceuticals has one of the most promising pipelines in the small to mid-cap space. It has two very promising compounds in development, INCB18424 for.

Biotech’s One-Trick Pony

The One-Trick Pony We’ve heard this many times- never bet on that one-trick pony. Risky bet. You’ll lose your shirt. So what does this one-trick pony thing look like? What.

The Promise Behind Celldex- ASCO 2010

The Promise Behind Celldex Celldex shares climbed steadily in the months leading up to the release of its ASCO abstracts, rising from $4.71 at the start of the year and.

Bionovo: novel approach, challenges ahead, but poised to move higher

The Women’s Health Initiative (WHI), a study that demonstrated several lethal side-effects of hormone replacement therapy (HRT), has left many pharmaceutical companies scrambling to advance alternative therapies to meet the.

Serada Half Price Sale: DepoMed’s Stock Price Poised to Climb

Several weeks ago, DepoMed (NASDAQ:DEPO), a specialty pharmaceutical company, announced positive phase 3 trial results for the treatment of Post Herpetic Neuralgia (‘PHN’) with DM1796. But DepoMed’s news of success.

Browsing 20 / 3 articles